Monoclonal Antibody-Based Targeted Therapy in Breast Cancer
Authors: Kadri Altundag1; Francisco J. Esteva1; Banu Arun1
Source: Current Medicinal Chemistry - Anti-Cancer Agents, Volume 5, Number 2, March 2005 , pp. 99-106(8)
Publisher: Bentham Science Publishers
- Free Content
- New Content
- Subscribed Content
- Free Trial Content
Abstract:
Advances in molecular biology have identified tumor markers that not only predict prognosis and therapeutic response but may also function as potential therapeutic targets. Activated growth factor receptors induce breast cancer cells to proliferate, invade, and metastasize in experimental models. Overexpression of growth factor receptors has been associated with a poor clinical outcome in breast cancer patients. Biological therapy with monoclonal antibody directed against growth factor receptor pathways became important targeted therapy in breast cancer and is being pursued on various fronts. The anti-HER2 antibody trastuzumab is approved in the metastatic setting and is now trying to find the place in the adjuvant setting. Phase II and III studies with antibodies directed against VEGF and EGFR are also ongoing.Keywords: breast cancer; biological therapy; egfr; her-2; monoclonal antibodies
Document Type: Review article
DOI: 10.2174/1568011053174846
Affiliations: 1: Department of Breast Medical Oncology, Unit 424, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas, 77030, USA.
- Free Content
- New Content
- Subscribed Content
- Free Trial Content
Click here for Page Help